Intracranial Solitary Fibrous Tumor: A “New” Challenge for PET Radiopharmaceuticals

Angela Sardaro 1, Paolo Mammucci 2, Antonio Rosario Pisani 2,* , Dino Rubini 2, Anna Giulia Nappi 2, Lilia Bardoscia 3 and Giuseppe Rubini 2

1 Section of Radiology and Radiation Oncology, Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, 70124 Bari, Italy
2 Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari Aldo Moro, Piazza Giulio Cesare 11, 70124 Bari, Italy
3 Radiation Oncology Unit, S. Luca Hospital, Healthcare Company Tuscany Nord Ovest, 55100 Lucca, Italy
* Correspondence: apisani71@libero.it; Tel.: +39-080-5594388

Abstract: Solitary fibrous tumor (SFT) of the central nervous system, previously named and classified with the term hemangiopericytoma (HPC), is rare and accounts for less than 1% of all intracranial tumors. Despite its benign nature, it has a malignant behavior due to the high rate of recurrence and distant metastasis, occurring in up to 50% of cases. Surgical resection of the tumor is the treatment of choice. Radiotherapy represents the gold standard in the case of post-surgery residual disease, relapse, and distant metastases. In this context, imaging plays a crucial role in identifying the personalized therapeutic decision for each patient. Although the referring imaging approach in SFT is morphologic, an emerging role of positron emission tomography (PET) has been reported in the literature. However, there is still a debate on which radiotracers have the best accuracy for studying these uncommon tumors because of the histological or biological heterogeneity of SFT.

Keywords: solitary fibrous tumor; hemangiopericytoma; PET/CT; fluorodeoxyglucose; fluorocholine; non-FDG radiopharmaceuticals

1. Introduction

In 2021, the latest and most recent version of the 5th edition of WHO Classification of Tumors of the Central Nervous System (CNS5) was published. One of the most important innovations is the introduction of a new classification of tumor types and subtypes, thanks to novel diagnostic technologies such as DNA methylome profiling. Focusing on mesenchymal, non-meningothelial tumors, the hybrid term solitary fibrous tumor/hemangiopericytoma (SFT/HPC), previously used in the 2016 WHO classification, has been abandoned in favor of the use of the term solitary fibrous tumor (SFT) alone to fully comply with the nomenclature of soft-tissue pathology [1].

SFTs are rare mesenchymal malignancies of soft-tissue cells with a high percentage of recurrence. In particular, intracranial SFTs constitute 2.5% of meningeal neoplasms and less than 1% of all intracranial tumors [2]. At present, magnetic resonance imaging has a well-established role in the identification and diagnosis of this rare tumor. However, because of SFTs’ high tendency to have locoregional recurrences and distant metastases, in recent years, multimodality imaging, particularly positron emission tomography/computed tomography (PET/CT), has shown an increasingly significant role, thanks to the possibility of obtaining both metabolic and morphological information in a single scan. Furthermore, it is a non-invasive and total-body examination, with high sensitivity and specificity [3,4].

SFTs are rare mesenchymal malignancies of soft-tissue cells with a high percentage of recurrence. In particular, intracranial SFTs constitute 2.5% of meningeal neoplasms and less than 1% of all intracranial tumors [2]. At present, magnetic resonance imaging has a well-established role in the identification and diagnosis of this rare tumor. However, because of SFTs’ high tendency to have locoregional recurrences and distant metastases, in recent years, multimodality imaging, particularly positron emission tomography/computed tomography (PET/CT), has shown an increasingly significant role, thanks to the possibility of obtaining both metabolic and morphological information in a single scan. Furthermore, it is a non-invasive and total-body examination, with high sensitivity and specificity [3,4].

We aimed to present a brief critical overview of the role of PET/CT in diagnosing, local disease relapse, or distant metastases evaluation in the treatment response to surgery and/or radiotherapy and in the follow-up of patients affected by intracranial SFT.
2. Solitary Fibrous Tumor

SFT is a very rare and uncommon neoplasm, accounting for only 1.6% of all central nervous system (CNS) tumors. In the 2016 World Health Organization (WHO) classification of CNS tumors, SFTs and HPCs constituted a single disease entity, known as SFT/HPC. However, in the last recent update of WHO CNS5, the term “hemangiopericytoma” was deleted to emphasize the biological similarities within tumor types and to align with the soft-tissue pathology nomenclature [1].

This tumor was firstly known by the term hemangiopericytoma, coined by Stout and Murray in 1942, to highlight the origin from the capillary and postcapillary venules of pericytes. It can occur in any anatomical body region with the presence of capillaries and a typical localization involves the meninges of the dura mater, with an incidence of 16–33% of SFTs in the head or neck [5]. From a histological point of view, these tumors are characterized by spindle mesenchymal cells with a rich vascular component. Usually, the presence of hypercellularity, hemorrhage and/or necrosis, pleomorphic nuclei, and foci of dedifferentiation suggests a malignant behavior [6]. The tumor immunophenotype can be characterized by CD34 and smooth-muscle-actin positivity and by S100 protein, CK pool, and desmin negativity [7]. In accordance with previous immunohistochemical features, the new WHO CNS5 reported that STFs show NAB2 and STAT6 gene fusion as well as STAT6 overexpression [2].

Even many years after the end of the first (line) treatment, locoregional relapses, as well as distant metastases, are very common, and a prompt diagnosis could be crucial for better patient management. However, probably due to SFTs’ rarity, there are no clear recommendations on the best imaging method to evaluate them [8]. The literature is characterized by small-sample-size studies and case series, showing that complete surgical resection with clear margins is the treatment of choice. However, one year after the stand-alone surgery option, a very high percentage of disease relapse, rating from 88 to 100%, may occur as a result of tumor infiltration in adjacent vascular structures with a worsening of survival [9]. Stereotaxic radiosurgery has emerged as a promising adjuvant treatment to reduce the relapse rate of the disease [2]. In an updated overview on radiation therapy options for intracranial HPC, Ciliberti and colleagues showed that postoperative radiotherapy (RT) can lead to a consistent decrease in local recurrences, moving from 88% to 12.5%, and longer relapse-free survival [9]. In addition, when the lesion is close to critical anatomical structures, stereotactic radiotherapy can be considered. However, even after a wide surgical resection or a combined surgery–radiotherapy treatment, recurrences and metastases can subsequently occur in up to 50% of cases [10,11].

In this scenario, imaging can play a crucial role in potentially guiding the best therapeutic decision and in establishing tailored treatment.

Although the referring imaging approach in SFTs is morphologic, it may fail in differentiating between scar tissue and viable tumor in post-treatment evaluation. For this purpose, PET has demonstrated a promising role [12,13].

3. Search Strategy

A literature search was conducted on the Medline (PubMed) database including all articles published up to 30 June 2022. The following keywords were entered to rule the search: “intracranial solitary fibrous tumor” AND “positron emission tomography”, AND “PET” AND “nuclear medicine”, “hemangiopericytoma” AND “positron emission tomography” AND “PET” AND “nuclear medicine”, “intracranial hemangiopericytoma” AND “positron emission tomography” AND “PET” AND “nuclear medicine”. Only articles edited in English in the last 10 years were included in this review. After reading the abstracts, some articles were excluded because they did not meet the goal of our review in evaluating the use of PET/CT in patients affected by intracranial SFT/HPC. For the same reason, some articles were not considered in the final draft after reading the full text. To identify supplementary eligible articles, additional references were searched from the retrieved review articles. Due to the rarity of SFT, most of the articles in the literature are represented by case reports and interesting images. The main characteristics of the included studies are detailed in Table 1.
Table 1. Main characteristics of the included studies of intracranial SFTs/HPCs with probable distant metastases studied using PET/CT or scintigraphy with $^{111}$In-Pentreotide ($n=16$).

| Case | Authors | Year | Age, Sex | Intracranial Primitive Site | Metastatic Sites | Radiopharmaceuticals | Qualitative and Semiquantitative Uptake Level |
|------|---------|------|----------|-----------------------------|------------------|----------------------|---------------------------------------------|
| 1    | Z. Wu et al. [14] | 2015 | 25, M    | Right occipital lobe        | Lungs, bones     | $^{18}$F-FDG         | Mild-moderate SUVmean 4.9—SUVmax 8.1        |
| 2    | H. Cheung et al. [15] | 2018 | 67, F    | Right posterior occipital calvary | Paravertebral, bones, lymph nodes | $^{18}$F-FDG         | Mild *                                     |
| 3    | K.P. Cheng et al. [8] | 2017 | 41, F    | Intracranial meninges       | Bones            | $^{18}$F-FDG         | Intense *                                  |
| 4    | T. Hiraide et al. [16] | 2012 | 41, M    | Cerebellum                  | Kidneys, lungs, pancreas | $^{18}$F-FDG         | Intense *                                  |
| 5    | X. Liu et al. [17] | 2021 | 40, M    | Fronto-parietal             | Kidney           | $^{18}$F-FDG         | Mild, SUVmax 3.17                          |
| 6    | H. N. Hayenga et al. [18] | 2019 | 34, F    | Right cerebellopontine angle | Thoracic spine   | $^{18}$F-FDG         | Low *                                      |
| 7    | A. Yasen et al. [19] | 2020 | 62, F    | Frontal cerebral convex, parafalk | Liver            | $^{18}$F-FDG         | Absent                                     |
| 8    | H. Grunig et al. [20] | 2021 | 46, F    | Intracranial dura           | Liver, muscles   | $^{18}$F-FDG         | High-moderate SUVmax 9.0                   |
| 9    | Sardaro et al. [7] | 2021 | 69, M    | Left orbit                  |                  | $^{18}$F-FDG         | Absent                                     |
| 10   | Jehanno et al. [21] | 2019 | 50, M    | Right sphenoid-orbital region |                  | $^{18}$F-FDG         | Low, SUVmax 3.5                            |
| 11   | Lavacchi et al. [22] | 2020 | 64, F    | Posterior fossa             | Liver, kidneys, lungs | $^{111}$In-Pentreotide | Intense *                                  |
|      |         |      | 35, M    | Falx cerebri                | Liver            | $^{18}$F-FDG         | Intense *                                  |
| 12   | G. Kota et al. [23] | 2013 | 54, F    | Right optic nerve sheath    | Bones            | $^{111}$In-Pentreotide | Intense *                                  |
| 13   | T. Hung et al. [24] | 2016 | 68, F    | Not specified               | Lungs            | $^{18}$F-FDG         | Minimal *                                  |
| 14   | K.C. Patro et al. [25] | 2018 | 53, F    | Right posterior cranial fossa | Bones, liver     | $^{18}$F-FDG         | Low *                                      |
| 15   | Zhang et al. [26] | 2021 | 23, F    | Right front lobe            |                  | $^{18}$F-FDG         | Low, SUVmax 1.6                            |
| 16   | I. Jong et al. [27] | 2013 | 47, M    | Not specified               | Bones            | $^{18}$F-FDG         | Intense *                                  |

Abbreviations: FDG = fluorodeoxyglucose; SUVmean = average standardized uptake value; SUVmax = maximum standardized uptake value; FCH = fluorocholine; PSMA = prostate-specific membrane antigen; DOTATATE = dodecane tetra-acetic acid tyrosine-3-octreotate; FAPI = fibroblast-activation-protein inhibitor. Annotation: * = semiquantitative parameters not known.
4. Evidence-Based Medicine of PET/CT in Intracranial Solitary Fibrous Tumor/Hemangiopericytoma

In the last decade, PET/CT emerged as a non-invasive, whole-body diagnostic tool with an important role in diagnosis, staging, detecting possible disease relapses and distant metastases, differentiating between scar and viable tissues, and in the follow-up of patients affected by SFT. To the best of our knowledge, this is the first literature review that focuses on the role of PET/CT in intracranial SFTs. This topic could reveal to be great interest in identifying the best accurate PET radiopharmaceutical to diagnose and follow up this rare tumor. Indeed, despite its benign nature, SFT has a malignant behavior, with a characteristic high rate of locoregional relapse and of distant metastases due to its hypervascularity.

To date, most of the authors referred to $^{18}$F-FDG as the main PET radiotracer used in this oncological field to assess glucose metabolism activity, usually increased in neoplastic cells. $^{18}$F-FDG is intracellularly trapped after GLUT-transporter uptake and hexokinase phosphorylation in glucose-6-phosphate. The hypercellularity of SFT lesions may support its application in these cases. However, the intense physiological uptake of the brain makes adequate $^{18}$F-FDG PET imaging of intracranial tumors a challenge [21]. In some cases of SFT/HPC, $^{18}$F-FDG PET may be helpful to differentiate necrotic from viable tumors, with both hypoenhancing on CT but with different metabolic activities on PET, significantly influencing the treatment decision [28]. Generally, FDG uptake in SFT/HPC cells is decreased compared with the surrounding tissue, while intense $^{18}$F-FDG hypermetabolism may suggest the presence of a more malignant variety of SFT, with a significant impact on prognosis [22]. The relatively low SUVmax values in $^{18}$F-FDG PET studies could help to differentiate SFT from other malignancies. In addition, a differential diagnosis with respect to other tumors may be facilitated by a dual-tracer technique to compare different image patterns developed by two PET radiotracers. For example, low glucose metabolism in contrast to high $^{11}$C-Methionine uptake may help to differentiate HPC from meningioma [29].

The high probability of developing metastases linked to the malignant behavior of this mesenchymal tumor makes $^{18}$F-FDG PET/CT a potential ideal tool to ensure adequate whole-body examination and to correctly guide therapeutic decision making with a tailored approach [8].

In Wu et al.’s case report, $^{18}$F-FDG PET/CT was performed to restage a 25-year-old man affected by a malignant SFT of the right occipital lobe primarily treated with multiple craniotomies and postoperative conformal RT. PET/CT showed both intracranial disease recurrence and, above all, massive bilateral pulmonary lesions and multiple bone metastases [14].

Cheung et al. confirmed the fundamental role of $^{18}$F-FDG PET/CT in identifying distant metastases from SFT/HPC describing a case of a 67-year-old woman treated with the resection of a paravertebral soft-tissue mass with histological diagnosis of HPC. After eight years, MRI detected three histologically proven SFT/HPC lesions of the right posterior occipital calvarium, while $^{18}$F-FDG PET/CT showed multiple hypermetabolic lesions involving lymph nodes and bone from the calvarium to the sacrum [15].

Furthermore, the literature reports a case of 41-year-old man surgically treated for a cerebellar HPC. After twenty-two years, the patient experienced multiple renal and pulmonary metastases, pathologically proven to be HPC, and a local intracranial recurrence, all of them surgically treated. Two years later, abdominal CT revealed a pancreatic tumor, confirmed with whole-body $^{18}$F-FDG PET/CT with intense radiopharmaceutical uptake. This lesion was surgically removed and histopathological examination confirmed the diagnosis of HPC, with similar pathological findings to those of the original cerebellum HPC [16].

However, in some cases, $^{18}$F-FDG PET/CT may not prove to be adequately reliable in accurately detecting all SFT/HPC lesions, since low–moderate glucose metabolism in both primary and metastatic lesions can be observed. Recently, Liu Xiao et al. reported a case of a 40-year-old patient affected by intracranial STF/HPC with a left renal metastatic lesion showing only mild $^{18}$F-FDG uptake and homogeneous contrast enhancement after contrast-medium administration [17].
Similarly, Hayenga and his colleagues reported a case of a 34-year-old woman affected by HPC of the right cerebellopontine angle (CPA) who underwent surgical treatment combined with postoperative RT. After 3 years of disease-free interval, $^{18}$F-FDG PET/CT was performed showing low FDG avidity both in intracranial and extracranial recurrences of the spinal canal [18]. Consistent with these reports, Yasen and colleagues reported negative FDG uptake in the presence of HPC recurrence and metastasis. Namely, a woman with bilateral-frontal-cerebral-convex and parafalx HPC was surgically treated and underwent $^{18}$F-FDG PET/CT six years later, demonstrating high-density lesions on CT images without FDG uptake and low-density solid lesions without FDG uptake in the frontal lobe parafalx and in the right posterior and left outer lobes of the liver, respectively. The histological examination of calvarium and hepatic lesions showed homogeneous features of HPC tumor [19]. These are examples of SFT/HPC lesions with low glucose metabolism, almost similar to background FDG activity, suggesting that $^{18}$F-FDG PET/CT should not be the only diagnostic tool to be used in this set of patients, especially for the detection of craniospinal-axis SFT/HPC [18].

Another issue that deserves consideration and that may limit $^{18}$F-FDG PET/CT performance is the FDG heterogeneous uptake between primitive SFT/HPC and metastatic lesions. In this regard, Grunig and colleagues reported a case of a 46-year-old patient with high FDG uptake in primary-dura HPC and liver metastases, but moderate radiopharmaceutical uptake in a leg-muscle tissue lesion [20].

In relation to these $^{18}$F-FDG PET/CT limitations, current literature debates which is the most accurate PET radiopharmaceutical to adequately study this rare benign, but with malignant behavior, tumor with possible histological or biological heterogeneity.

Some authors highlighted that SFT/HPC shows different spectral patterns on MR spectroscopy, with dominant Choline expression [30,31]. This feature suggested the potential usefulness of radiolabeled Choline as an ideal PET radiopharmaceutical in SFT/HPC detection [21,32,33]. Choline is a precursor of the biosynthesis of cell-membrane phospholipids, which is increased in the most malignant tumors, including SFTs. In fact, once intracellular uptake is performed by specific transporters, Choline is phosphorylated by choline-kase in phosphorylcholine and incorporated into the cell membrane [34–36]. Considering the anatomical proximity with brain parenchyma, a further advantage of $^{18}$F-FCH PET/CT is the very low brain uptake with a favorable tumor-to-background ratio with a better image contrast. The low physiological distribution of Choline in normal white and grey matter may help to distinguish different brain tumors with increased uptake from benign lesions and radiation necrosis with the lowest uptake [36]. In the case report by Sardaro et al., $^{18}$F-Fluorocholine ($^{18}$F-FCH) PET/CT showed superior performance compared with $^{18}$F-FDG PET/CT in a 69-year-old patient with two local recurrences of malignant orbital SFT, playing a crucial role in differentiating between small recurrences/pathological lesions and scar tissue in brain parenchyma (Figure 1) [7]. The favorable Choline tumor-to-background ratio [37] allows better and well-defined visualization of the lesion with intracranial localization to be obtained [38].

Similarly, Jehanno et al. reported a case of a 50-year-old male with a previous history of surgically treated intracranial HPC who experienced a local recurrence eighteen months later. After partial resection, the authors performed both preoperative $^{18}$F-FDG PET/CT and $^{18}$F-FCH PET/CT for the treatment planning of residual disease located along the optic nerve. $^{18}$F-FDG PET/CT did not show any significant uptake. Conversely, $^{18}$F-FCH PET/CT precisely detected an intense radiopharmaceutical uptake of residual disease in the retro-orbital region, more properly guiding the following RT [21].
was restaged 18 years after surgical treatment due to an
pressed in the neovasculature endothelium of some brain tumors, such as gliomas with
(a woman with bilateral-frontal-cerebral-convex and parafalx HPC was surgically treated
reported negative FDG uptake in the presence of HPC recurrence and metastasis. Namely,
side of the left orbit, strongly suspected of disease relapse (red arrow). (B) Two weeks later, 18F-FDG PET/CT showed no radiopharmaceutical uptake in the left supraorbital region (red arrow). (C) Conversely, after seven days, 18F-FCH PET/CT showed intense uptake in the aforementioned lesion (red arrow; SUVmax 6.8).

Some authors reported SFT lesions immunohistochemically and histologically char-
eterized by a high expression of somatostatin receptor (SSRs), especially subtype 2, well
studied with somatostatin-receptor molecular imaging methods. Lavacchi and colleagues
reported a case of an intracranial SFT/HPC with distant metastasis studied with 111In
Pentetreotide, a gamma-emitter radiolabeled somatostatin analogue, able to target the
highly expressed SSRs in anecdotal SFT lesions, with potential theragnostic implication. In
Lavacchi et al.’s case, high radiopharmaceutical uptake was observed both in primitive and
distant metastases. Namely, a 64-year-old female affected by cranial-posterior-fossa SFT
was restaged 18 years after surgical treatment due to an 111In Pentetreotide scan having
detected multiple intracranial recurrences and hepatic, renal, and pulmonary metastases
with avid tracer uptake [22]. Similarly, high SSR expression in intracranial and extracranial
lesions was detected with a 111In-Pentetreotide scan in a 54-year-old woman with intracranial
HPC of the right optic nerve sheath and bone distant metastases. In the same patient, low
FDG uptake in the aforementioned sites confirmed the unreliability of 18F-FDG PET/CT
in some cases [23]. Furthermore, 68Ga-Dodecane tetra-acetic acid tyrosine-3-octreotate
(68Ga-DOTATATE) is a PET radiopharmaceutical usually used for neuroendocrine-tumor
imaging and now increasingly considered as an adjunctive imaging tracer for multiple
solid neoplasms, including mesenchymal tumors [39]. Similarly to 111In-Pentetreotide,
68Ga-DOTATATE is a positron-emitter radiolabeled somatostatin analogue able to reveal a
high concentration of surface SSRs, with the advantages of superior spatial resolution
and accuracy, faster acquisition and lower radiation exposure [24]. In particular, Hung
et al. found negligible FDG uptake but intense 68Ga-DOTATATE avidity of pulmonary
metastases in a 68-year-old woman affected by primitive intracranial HPC [24].

In addition to FDG and choline, the literature reports the use of other PET radiotracers
for the identification of this uncommon neoplasm. In some cases, HPC/SFTs may show
high 68Ga-Prostate-Specific Membrane Antigen (68Ga-PSMA) avidity [40]. PSMA is a
type II integral transmembrane glycoprotein, known as folate-hydrolase 1 or glutamate-
carboxypeptidase II, with neuropeptidase activity. It was found to be surprisingly overex-
pressed in the neovasculature endothelium of some brain tumors, such as gliomas with
significant angiogenic activity, whereas low PSMA expression can be found in tumor cells
or healthy brain. Low PSMA uptake in the normal brain parenchyma and its high tumor-
to-background ratio allows an accurate localization of intracranial lesions with PSMA
overexpression to be performed, which seems not to be related to the type of brain malig-
nancy. The literature reports higher PSMA-uptake in high-grade gliomas and metastatic brain tumors than in central-nervous-system lymphoma and radiation necrosis, while there are no data about the differential diagnosis with SFT/HPC because of the rarity of this tumor [25,36,41]. Patro and colleagues described intense \( ^{68} \text{Ga-PSMA} \) avidity in all hepatic and bones metastases in a 53-year-old woman with primitive right-posterior-cranial-fossa HPC, in contrast with the low glucose metabolism of these lesions, probably due to PSMA overexpression in tumor neovascularure [25].

Interestingly, Zhang et al. showed an intense \( ^{68} \text{Ga-Fibroblast-activation-protein-inhibitor} \) \( (^{68} \text{Ga-FAPI}) \) (compared with low \( ^{18} \text{F-FDG} \) uptake) in a 23-year-old female patient with SFT/HPC of the right frontal lobe. Fibroblast activation protein (FAP) is strongly overexpressed in the stroma of human cancers, including SFTs, and its quinoline-based FAP inhibitor can be internalized after binding to the FAP enzymatic domain. This suggests the potential role of this new PET radiotracer with a specific target for FAP, which can be overexpressed in this mesenchymal tumor [26,42]. The Acetate property of being a fatty acid precursor and thus an indirect biomarker of fatty acid synthesis can be exploited. In fact, ACT is converted to Acetyl Co-A, which is incorporated into cholesterol and fatty acids. Jong et al. reported a single case of dual-tracer \( ^{11} \text{C-acetate} \) \( (^{11} \text{C-ACT}) \) and \( ^{18} \text{F-FDG} \) PET/CT in a 47-year-old male patient with intracranial HPC, showing significantly higher \( ^{11} \text{C-ACT} \) uptake of bone metastases than FDG uptake, probably due to the over-expression of fatty acid synthase in this kind of tumors [27,43].

5. Conclusions

PET/CT could play a fundamental role in diagnosis, staging, post-treatment evaluation (surgery, radiotherapy, chemotherapy), disease relapses and distant metastases detection, and follow-up of patients affected by intracranial SFT, a benign but inherently aggressive tumor.

However, the literature still debates which type of PET radiopharmaceutical could guarantee the best accuracy for correctly and promptly guiding the management of this set of patients. \( ^{18} \text{F-FDG PET/CT} \) shows an extremely heterogeneous behavior, with modest or low radiopharmaceutical uptake in most cases of single- or dual-tracer studies, variable sensitivity and low reliability.

Compared with \( ^{18} \text{F-FDG PET/CT} \), \( ^{18} \text{F-FCH PET/CT} \) appears to be superior in detecting intracranial SFTs thanks to the histological and biological features of SFT and a favorable tumor-to-background ratio.

Other radiopharmaceuticals labeled with Gallium 68 also demonstrate a promising role in SFT-relapse or distant-metastases detection.

The current literature shows that \( ^{18} \text{F-FDG} \) is the most widely used radiopharmaceutical in this set of patients. However, although fully aware that numerous studies are needed to identify which radiotracer to use based on the biological and histological characteristics of this rare tumor, our limited experience unquestionably reveals the superiority of \( ^{18} \text{F-FCH PET/CT} \), compared with \( ^{18} \text{F-FDG PET/CT} \), for the study of patients with intracranial SFT. \( ^{18} \text{F-FCH PET/CT} \) can play a significant role in providing information for both local recurrence and distant metastases.

Therefore, for all the aforementioned reasons, it would be desirable to include PET/CT as a diagnostic, sensitive, non-invasive method in the guidelines for the management of SFT.

Author Contributions: Conceptualization, P.M.; methodology, P.M. and A.G.N.; validation, A.S.; formal analysis, A.R.P. and L.B.; investigation, P.M. and D.R.; data curation, A.R.P. and L.B.; writing—original draft preparation, D.R. and A.G.N.; writing—review and editing, A.S. and P.M.; supervision, G.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research study received no external funding.

Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Informed consent was obtained from the subject included in the analysis.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021, 23, 1231–1251. [CrossRef] [PubMed]

2. Allen, A.J.; Labella, D.A.; Richardsson, K.M.; Sheehan, J.P.; Kersh, C.R. Recurrent Solitary Fibrous Tumor (Intracranial Hemangiopericytoma) Treated with a Novel Combined-Modality Radiosurgery Technique: A Case Report and Review of the Literature. Front. Oncol. 2022, 12, 907324. [CrossRef] [PubMed]

3. Altini, C.; Lavelli, V.; Ruta, R.; Ferrari, C.; Nappi, A.G.; Pisani, A.; Sardaro, A.; Rubini, G. Typical and atypical PET/CT findings in non-cancerous conditions. Hell. J. Nucl. Med. 2020, 23, 48–59. [CrossRef]

4. Altini, C.; Asabella, A.N.; Lavelli, V.; Bianco, G.; Ungaro, A.; Pisani, A.; Merenda, N.; Ferrari, C.; Rubini, G. Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer. Recent. Prog. Med. 2019, 110, 144–150. [CrossRef] [PubMed]

5. Stout, A.P.; Murray, M.R. Hemangiopericytoma: A vascular tumor featuring Zimmermann’s pericytes. Ann. Surg. 1942, 116, 26–33. [CrossRef] [PubMed]

6. Demicco, E.G.; Park, M.S.; Araujo, D.M.; Fox, P.S.; Bassett, R.L.; Pollock, R.E.; Lazar, A.J.; Wang, W.L. Solitary fibrous tumor: A clinicopathological study of 110 cases and proposed risk assessment model. Mod. Pathol. 2012, 25, 1298–1306. [CrossRef]

7. Sardaro, A.; Ferrari, C.; Mammiucchi, P.; Piscitelli, D.; Rubini, D.; Maggialletti, N. The significant role of multimodality imaging with 18 Fluorocholine PET/CT in relapsed intracranial hemangiopericytoma. Rev. Esp. Med. Nucl. Imagen Mol. 2021, in press. [CrossRef]

8. Cheng, K.P.; Wong, W.J.; Hashim, S.; Mun, K.S. Hemangiopericytoma 11 years later: Delayed recurrence of a rare soft tissue sarcoma. J. Thorac. Dis. 2017, 9, E752–E756. [CrossRef] [PubMed]

9. Ciliberti, M.P.; D’Agostino, R.; Gabrieli, L.; Nikolau, A.; Sardaro, A. The radiation therapy options of intracranial hemangiopericytoma: An overview and update on a rare vascular mesenchymal tumor. Oncol. Rev. 2018, 12, 63–68. [CrossRef]

10. Ramsey, H.J. Fine structure of hemangiopericytoma and hemangio-endothelioma. Cancer 1966, 19, 2005–2018. [CrossRef]

11. d’Amore, E.S.G.; Manivel, J.C.; Sung, J.H. Soft-tissue and meningeal hemangiopericytomas: An immunohistochemical and ultrastructural study. Hum. Pathol. 1990, 21, 414–423. [CrossRef]

12. Purandare, N.C.; Dua, S.G.; Rekhi, B.; Shah, S.; Sharma, A.R.; Rangarajan, V. Metastatic recurrence of an intracranial hemangiopericytoma 8 years after treatment: Report of a case with emphasis on the role of PET/CT in follow-up. Cancer Imaging 2010, 10, 117–120. [CrossRef] [PubMed]

13. Jacobs, A.H.; Kracht, L.W.; Gossmann, A.; Rüger, M.A.; Thomas, A.V.; Thiel, A.; Herholz, K. Imaging in neurooncology. NeuroRx 2005, 2, 333–347. [CrossRef] [PubMed]

14. Wu, Z.; Yang, H.; Meng, D.; Ding, Y. Rapid recurrence and bilateral lungs, multiple bone metastasis of malignant solitary fibrous tumor of the right occipital lobe: Report of a case and review. Diagn. Pathol. 2015, 10, 91. [CrossRef] [PubMed]

15. Cheung, H.; Lawhn-Heath, C.; Lopez, G.; Vella, M.; Aparici, C.M. Metastatic cervical paravertebral solitary fibrous tumor detected by fluorodeoxyglucose positron emission tomography-computed tomography. Radiol. Case Rep. 2018, 13, 464–467. [CrossRef] [PubMed]

16. Hiraide, T.; Sakaguchi, T.; Shibasaki, Y.; Morita, Y.; Suzuki, A.; Inaba, K.; Tokuyama, T.; Baba, S.; Suzuki, S.; Kondo, H. Pancreatic metastases of cerebellar hemangiopericytoma occurring 24 years after initial presentation: Report of a case. Surg. Today 2014, 44, 558–563. [CrossRef]

17. Xiao, L.; Li, L. Bilateral renal metastasis from intracranial solitary fibrous tumor/hemangiopericytoma revealed on 18 F-FDG PET/CT and contrast-enhanced CT. Hell. J. Nucl. Med. 2021, 24, 272–273. [CrossRef] [PubMed]

18. Hayenga, H.N.; Bishop, A.J.; Wardak, Z.; Sen, C.; Mickey, B. Intraspinal Dissemination and Local Recurrence of an Intracranial Hemangiopericytoma. World Neurosurg. 2019, 123, 68–75. [CrossRef]

19. Yasen, A.; Ran, B.; Jiang, T.; Maimaitinijia, Y.; Zhang, R.; Guo, Q.; Shao, Y.; Aji, T.; Wen, H. Liver metastasis and local recurrence of meningeal hemangiopericytoma: A case report. Transl. Cancer Res. 2020, 9, 1278–1283. [CrossRef]

20. Grünig, H.; Skawran, S.; Stolzmann, P.; Messeri, M.; Huellner, M.W. A Rare Case of Metastatic Solitary Fibrous Tumor (Hemangiopericytoma) of the Dura on 18F-FDG PET/CT. Clin. Nucl. Med. 2021, 46, 768–769. [CrossRef]

21. Jehanno, N.; Cassou-Mounat, T.; Mammar, H.; Luporsi, M.; Huetch, V. 18F-Choline PET/CT Imaging for Intracranial Hemangiopericytoma Recurrence. Clin. Nucl. Med. 2019, 44, e305–e307. [CrossRef]

22. Lavacchi, D.; Antonuzzo, L.; Briganti, V.; Berti, V.; Abenavoli, E.M.; Linguati, F.; Messerini, L.; Giaccone, G. Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: Description of two cases with radically different behaviors and review of the literature. Anti-Cancer Drugs 2020, 31, 646–651. [CrossRef] [PubMed]

23. Kota, G.; Gupta, P.; Lesser, G.J.; Wilson, J.A.; Mintz, A. Somatostatin receptor molecular imaging for metastatic intracranial hemangiopericytoma. Clin. Nucl. Med. 2013, 38, 984–987. [CrossRef]
24. Hung, T.J.; MacDonald, W.; Muir, T.; Celliers, L.; Al-Ogâli, Z. 68Ga DOTATATE PET/CT of Non-FDG-Avid pulmonary metastatic hemangiopericytoma. Clin. Nucl. Med. 2016, 41, 779–780. [CrossRef] [PubMed]

25. Patro, K.C.; Palla, M.; Kashyap, R. Unusual Case of Metastatic Intracranial Hemangiopericytoma and Emphasis on Role of 68Ga-PSMA PET in Imaging. Clin. Nucl. Med. 2018, 43, e331–e333. [CrossRef] [PubMed]

26. Zhang, Y.; Cai, J.; Wu, Z.; Yao, S.; Miao, W. Intense [68 Ga] Ga-FAPI-04 uptake in solitary fibrous tumor/hemangiopericytoma of the central nervous system. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 4103–4104. [CrossRef] [PubMed]

27. Jong, I.; Chen, S.; Leung, Y.L.; Cheung, S.K.; Ho, C.-L. 11C-acetate PET/CT in a case of recurrent hemangiopericytoma. Clin. Nucl. Med. 2014, 39, 478–479. [CrossRef]

28. Chan, W.S.W.; Zhang, J.; Khong, P.L. 18F-FDG-PET-CT imaging findings of recurrent intracranial haemangiopericytoma with distant metastases. Br. J. Radiol. 2010, 83, e172–e174. [CrossRef] [PubMed]

29. Kracht, L.W.; Bauer, A.; Herholz, K.; Terstegge, K.; Friese, M.; Schröder, R.; Heiss, W.D. Positron emission tomography in a case of intracranial hemangiopericytoma. J. Comput. Assist. Tomogr. 1999, 23, 365–368. [CrossRef]

30. Cho, Y.D.; Choi, G.H.; Lee, S.P.; Kim, J.K. The transport of choline. Drug Dev. Ind. Pharm. 2002, 28, 749–771. [CrossRef] [PubMed]

31. Mama, N.; Ben Abdallah, A.; Hasni, I.; Kadri, K.; Arifa, N.; Ladib, M.; Tlili-Graiess, K. MR imaging of intracranial hemangiopericytomas. J. Neuroradiol. 2010, 37, 296–306. [CrossRef] [PubMed]

32. Ito, S.; Yokoyama, J.; Yoshimoto, H.; Yazawa, M.; Kazuo, K.; Hanaguri, M.; Ohba, S.; Fujimaki, M.; Ikeda, K. Usefulness of Choline-PET for the detection of residual hemangiopericytoma in the skull base: Comparison with FDG-PET. Head Face Med. 2012, 8, 3. [CrossRef] [PubMed]

33. Cuccurullo, V.; Di Stasio, G.D.; Evangelista, L.; Castoria, G.; Mansi, L. Biochemical and Pathophysiological Premises to Positron Emission Tomography with Choline Radiotracers. J. Cell. Physiol. 2017, 232, 270–275. [CrossRef] [PubMed]

34. Glunde, K.; Penet, M.F.; Jiang, L.; Jacobs, M.A.; Bhujwalla, Z.M. Choline metabolism-based molecular diagnosis of cancer: An update. Expert Rev. Mol. Diagn. 2015, 15, 735–747. [CrossRef] [PubMed]

35. Lockman, P.R.; Allen, D.D. The transport of choline. Drug Dev. Ind. Pharm. 2002, 28, 749–771. [CrossRef] [PubMed]

36. Alongi, P.; Quartuccio, N.; Arnone, A.; Kokomani, A.; Allocca, M.; Nappi, A.G.; Santo, G.; Mantarro, C.; Laudicella, R. Brain PET/CT using prostate cancer radiopharmaceutical agents in the evaluation of gliomas. Clin. Transl. Imaging 2020, 8, 433–448. [CrossRef]

37. Khan, N.; Oriuchi, N.; Ninomiya, H.; Higuchi, T.; Kamada, H.; Endo, K. Positron emission tomographic imaging with 11C-choline in differential diagnosis of head and neck tumors: Comparison with 18F-FDG PET. Ann. Nucl. Med. 2004, 18, 409–417. [CrossRef] [PubMed]

38. Dunet, V.; Pomoni, A.; Hottinger, A.; Nicod-Lalonde, M.; Prior, J.O. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: Systematic review and meta-analysis. Neuro Oncol. 2016, 18, 426–434. [CrossRef] [PubMed]

39. Veldhuijzen van Zanten, S.E.M.; Bos, E.M.; Verburg, F.A.; van Doormaal, P.J. Intracranial hemangiopericytoma showing excellent uptake on arterial injection of [68 Ga] DOTATATE. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 1673–1674. [CrossRef] [PubMed]

40. Hammes, J.; Kobe, C.; Hilgenberg, U.; Drzezga, A. Orbital Hemangiopericytoma in 68Ga-Prostate-Specific Membrane Antigen-HBED-CC PET/CT. J. Clin. Med. 2017, 42, 812–814. [CrossRef] [PubMed]

41. Matsuda, M.; Ishikawa, E.; Yamamoto, T.; Hatano, K.; Joraku, A.; Iizumi, Y.; Masuda, Y.; Nishiyama, H.; Matsumura, A. Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89 Zr-Df-IAB2M anti-PSMA minibody. J. Neurooncol. 2018, 138, 581–589. [CrossRef] [PubMed]

42. Giesel, F.L.; Adeberg, S.; Syed, M.; Lindner, T.; Jiménez-Franco, L.D.; Mavriopoulou, E.; Staudinger, F.; Tonndorf-Martini, E.; Regnery, S.; Rieken, S.; et al. FAPI-74 PET/CT Using Either 18 F-AIF or Cold-Kit 68 Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients. J. Nucl. Med. 2021, 62, 201–207. [CrossRef] [PubMed]

43. Schuster, D.M.; Nanni, C.; Fanti, S. PET Tracers Beyond FDG in Prostate Cancer. Semin. Nucl. Med. 2016, 46, 507–521. [CrossRef] [PubMed]